Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 18/20 | 0.43 |
| ▸ | TACR3 | P29371 | 3/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13484088 | 1.00 | TACR1 (0.43) | TACR1TACR3KCNH2 | |
| SCHEMBL14972564 | 1.00 | TACR1 (0.43) | TACR1TACR3KCNH2 | |
| SCHEMBL16726992 | 0.89 | TACR1 (0.36) | TACR1 | |
| SCHEMBL16727030 | 0.88 | RXRA (0.36) | TACR1 | |
| SCHEMBL16729460 | 0.86 | TACR1 (0.37) | TACR1TACR3 | |
| SCHEMBL16727026 | 0.84 | RXRA (0.41) | TACR1 | |
| SCHEMBL22719593 | 0.83 | ADAMTS4 (0.45) | — | |
| SCHEMBL29504989 | 0.83 | ADAMTS4 (0.45) | — | |
| SCHEMBL31676274 | 0.82 | CYP3A4 (0.35) | — | |
| SCHEMBL3058615 | 0.82 | KIF11 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3558298-B1 | ANTIDIABETIC SPIROCHROMAN COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| US-10968232-B2 | Antidiabetic spirochroman compounds | MERCK SHARP & DOHME CORP. (US) | 2021-04-06 | — | — | US | disclosed |
| US-20190337961-A1 | ANTIDIABETIC SPIROCHROMAN COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2019-11-07 | — | — | US | disclosed |
| EP-3558298-A1 | ANTIDIABETIC SPIROCHROMAN COMPOUNDS | Merck Sharp & Dohme Corp. (US) | 2019-10-30 | — | — | EP | disclosed |
| WO-2018118670-A1 | ANTIDIABETIC SPIROCHROMAN COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2018-06-28 | — | — | WO | disclosed |
| EP-2850083-B1 | SUBSTITUTED 3,4-DIHYDRO-2H-PYRIDO[1,2-A]PYRAZINE-1,6-DIONE DERIVATIVES USEFUL FOR THE TREATMENT OF (INTER ALIA) ALZHEIMER'S DISEASE | JANSSEN PHARMACEUTICALS INC (US) | 2016-04-27 | — | — | EP | disclosed |
| EP-2578574-B1 | OPTICALLY ACTIVE DIBENZYLAMINE DERIVATIVE, AND MANUFACTURING METHOD FOR SAME | KOWA CO (JP) | 2016-04-27 | — | — | EP | disclosed |
| US-9272966-B2 | Method for preparing optically active 1-bromo-1[3,5-bis(trifluoromethyl)phenyl]ethane | KOWA COMPANY, LTD. (JP) | 2016-03-01 | — | — | US | disclosed |
| US-9181245-B2 | Substituted pyrido[1,2-a]pyrazines and substituted pyrido[1,2-a][1,4]diazepines for the treatment of (inter alia) Alzheimer's disease | Janssen Pharmaceuticals, Inc. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20150141411-A1 | SUBSTITUTED 3,4-DIHYDRO-2H-PYRIDO[1,2-A]PYRAZINE-1,6-DIONE DERIVATIVES USEFUL FOR THE TREATMENT OF (INTER ALIA) ALZHEIMER'S DISEASE | CELLZOME LIMITED (GB) | 2015-05-21 | — | — | US | disclosed |
| US-8906895-B2 | Optically active dibenzylamine derivative, and method for preparing thereof | KOWA COMPANY, LTD. (JP) | 2014-12-09 | — | — | US | disclosed |
| US-20130225814-A1 | OPTICALLY ACTIVE DIBENZYLAMINE DERIVATIVE, AND METHOD FOR PREPARING THEREOF | KOWA COMPANY, LTD. (JP) | 2013-08-29 | — | — | US | disclosed |
| US-20130190540-A1 | METHOD FOR PREPARING OPTICALLY ACTIVE 1-BROMO-1-[3,5-BIS(TRIFLUOROMETHYL)PHENYL]ETHANE | KOWA COMPANY, LTD. (JP) | 2013-07-25 | — | — | US | disclosed |
| EP-2597079-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 1-BROMO-1-[3,5-BIS(TRIFLUOROMETHYL)PHENYL]ETHANE | Kowa Company Ltd. (JP) | 2013-05-29 | — | — | EP | disclosed |
| EP-2578574-A1 | OPTICALLY ACTIVE DIBENZYLAMINE DERIVATIVE, AND MANUFACTURING METHOD FOR SAME | Kowa Company, Ltd. (JP) | 2013-04-10 | — | — | EP | disclosed |
| US-7625887-B2 | Receptor agonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-01 | — | — | US | disclosed |
| US-20060199795-A1 | Receptor agonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-09-07 | — | — | US | disclosed |
| EP-1591120-A1 | RECEPTOR AGONISTS | Takeda Chemical Industries, Ltd. (JP) | 2005-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190540-A1 | METHOD FOR PREPARING OPTICALLY ACTIVE 1-BROMO-1-[3,5-BIS(TRIFLUOROMETHYL)PHENYL]ETHANE | RPP30, BRPF1, ALK | TACR1 747/4885TACR3 2240/4885KCNH2 257/4885 |
| US-10968232-B2 | Antidiabetic spirochroman compounds | GPR119, GPR52, GPR55 | TACR1 183/4885TACR3 470/4885KCNH2 1671/4885 |
| US-20190337961-A1 | ANTIDIABETIC SPIROCHROMAN COMPOUNDS | GPR119, GPR52, GPR55 | TACR1 183/4885TACR3 470/4885KCNH2 1671/4885 |
| US-20130225814-A1 | OPTICALLY ACTIVE DIBENZYLAMINE DERIVATIVE, AND METHOD FOR PREPARING THEREOF | PCSK9, LDLR, PCSK7 | TACR1 1937/4885TACR3 911/4885KCNH2 4545/4885 |
| US-20060199795-A1 | Receptor agonists | GPBAR1, GPR35, GPR55 | TACR1 49/4885TACR3 112/4885KCNH2 1042/4885 |
| US-20150141411-A1 | SUBSTITUTED 3,4-DIHYDRO-2H-PYRIDO[1,2-A]PYRAZINE-1,6-DIONE DERIVATIVES USEFUL FOR THE TREATMENT OF (INTER ALIA) ALZHEIMER'S DISEASE | BACE1, PSEN1, BACE2 | TACR1 709/4885TACR3 1606/4885KCNH2 2202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.